Olaf-Oliver Wolz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9774403/publications.pdf

Version: 2024-02-01

933264 1125617 14 579 10 13 citations h-index g-index papers 14 14 14 1299 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. Journal of Allergy and Clinical Immunology, 2017, 140, 1054-1067.e10.	1.5	105
2	B-cell–specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. Blood, 2016, 127, 2732-2741.	0.6	99
3	Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2. Wiener Klinische Wochenschrift, 2021, 133, 931-941.	1.0	79
4	The fungal ligand chitin directly binds $<$ scp $>$ TLR $<$ /scp $>$ 2 and triggers inflammation dependent on oligomer size. EMBO Reports, 2018, 19, .	2.0	75
5	Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization. Blood, 2014, 124, 3896-3904.	0.6	69
6	BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. Journal of Experimental Medicine, 2021, 218, .	4.2	33
7	HLA class I-restricted <i>MYD88</i> L265P-derived peptides as specific targets for lymphoma immunotherapy. Oncolmmunology, 2017, 6, e1219825.	2.1	28
8	Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities. Cancer Immunology, Immunotherapy, 2018, 67, 1797-1807.	2.0	26
9	A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. Hepatology, 2015, 62, 1375-1387.	3.6	25
10	HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. Blood, 2018, 132, 510-520.	0.6	25
11	Absence of Non-Canonical, Inhibitory MYD88 Splice Variants in B Cell Lymphomas Correlates With Sustained NF.κB Signaling. Frontiers in Immunology, 2021, 12, 616451.	2.2	8
12	A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant. Vaccines, 2022, 10, 508.	2.1	5
13	Examining Myddosome Formation by Luminescence-Based Mammalian Interactome Mapping (LUMIER). Methods in Molecular Biology, 2018, 1714, 119-130.	0.4	1
14	Safety and Immunogenicity of mRNA-LNP COVID-19 Vaccine CVnCoV in Latin American Adults; A Phase 2 Randomized Study. SSRN Electronic Journal, 0, , .	0.4	1